Puma Biotechnology, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; comparisons are primarily with FY2020. This is an annual filing, not a standalone Q4 report, and the supplied filing text does not provide separate Q4 financial results.
Business context
Puma is a biopharmaceutical company focused on oncology and relies principally on NERLYNX (neratinib), its sole marketed product. NERLYNX is approved in the U.S. for certain early-stage and advanced or metastatic HER2-positive breast cancer indications. Puma sells directly in the U.S. and uses sublicense partners in international markets; it also continues clinical development of neratinib for additional indications.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Total revenue | $253.2 million | $225.1 million |
| NERLYNX product revenue, net | $189.1 million | $196.7 million |
| License revenue | $51.8 million | $22.7 million |
| Royalty revenue | $12.3 million | $5.7 million |
| Cost of sales | $63.7 million | $39.4 million |
| Operating income (loss) | $1.3 million | $(30.4) million |
| Net loss | $(29.1) million | $(60.0) million |
| Net loss per share, basic and diluted | $(0.72) | $(1.52) |
| Cash provided by operating activities | $20.7 million | $0.8 million |
- Total revenue increased about 12%, but product revenue fell about 4%. Higher license and royalty revenue more than offset weaker product sales; license revenue included a significant upfront sublicense payment.
- Product revenue declined with approximately 13% fewer bottles sold and higher variable-consideration reserves, rising from about 16% to 19% of product revenue, mainly due to Medicaid claims and government chargebacks. Price increases partly offset the decline.
- Cost of sales rose by $24.3 million, principally due to a one-time $20.0 million license termination fee and higher royalty and license fees. Total revenue less cost of sales was approximately $189.5 million, or 74.8% of revenue, versus approximately $185.7 million, or 82.5%, in FY2020; this calculated measure reflects the unusual cost increase and revenue mix.
- SG&A was $116.3 million, down about 2%; R&D was $71.9 million, down about 26%, reflecting lower clinical activity, headcount and stock-based compensation. FY2021 stock-based compensation totaled $32.6 million, including $13.6 million related to extending the CEO’s warrant term.
- FY2021 net loss included $9.6 million of net legal verdict expense, $12.8 million of interest expense and an $8.1 million debt-extinguishment loss. Management’s non-GAAP adjustment excluding stock-based compensation showed $3.5 million adjusted net income; this is not GAAP profit and should not be treated as a substitute for the reported net loss.
- At year-end, cash and cash equivalents were $63.1 million and marketable securities were $19.0 million, totaling $82.1 million; working capital was $30.4 million. Restricted cash of approximately $12.2 million was separately reported and is not equivalent to unrestricted liquidity.
- Cash, cash equivalents and restricted cash decreased $22.2 million during FY2021. Operating cash flow was positive, while investing activities used $10.9 million and financing activities used $31.9 million, including debt refinancing costs and Pfizer milestone installments.
- Debt principal outstanding was $100.0 million; its balance-sheet carrying value, net of discounts and issuance costs, was $97.1 million. The Athyrium notes mature July 2026, bear a floating rate with an 8% base plus capped three-month LIBOR, and had a reported effective rate of 10.98% at year-end. Principal payments begin in 2024, with a 2% exit payment on principal repayments.
Material changes, outlook and commentary
- Puma refinanced its Oxford facility with $100.0 million of Athyrium notes in July 2021; the agreement permits up to $25.0 million of additional borrowing, subject to its terms. The company reported compliance with applicable covenants at December 31, 2021.
- Management said existing cash and marketable securities, together with anticipated product sales and sublicense proceeds, were expected to fund operating and capital needs for at least one year after filing. This expectation is conditional; management warned that revenue, development, COVID-19 and other changes could use cash faster or impair covenant compliance. No specific revenue or earnings guidance was provided.
- COVID-19 continued to affect commercial interactions and patient enrollment. On November 2, 2021, Puma restructured and reduced headcount by about 13%, primarily in commercial and research functions, recording approximately $1.2 million in severance expense.
- NERLYNX’s diarrhea risk remains commercially and clinically relevant. Final CONTROL trial results found grade 3 diarrhea rates of 13% with the two-week dose-escalation regimen and 21% with loperamide plus colestipol, compared with 39.8% in the historical ExteNET trial control. U.S., Canadian and Australian label changes for dose escalation had been approved by year-end.
- Two U.S. customers represented approximately 31% and 22% of product revenue, respectively, underscoring customer concentration. The company also depends on sublicensees internationally and third parties for manufacturing and supply.
Contingencies and key risks
- Hsu securities class action: A settlement of approximately $54.2 million was agreed in principle, with no liability judgment under its terms. The first $27.2 million installment was paid in January 2022 and the balance was due in June 2022; final court approval was still pending as described in the filing.
- Eshelman litigation: The appellate court affirmed liability but vacated the prior damages award and remanded for a new damages trial. Puma accrued approximately $2.9 million as its estimate of the most likely outcome; the ultimate amount and timing remained uncertain.
- Patent matters: Puma pursued infringement claims against AstraZeneca involving Tagrisso and against Sandoz concerning a proposed generic NERLYNX product. A generic applicant also filed an ANDA in China. Outcomes could affect intellectual-property protection, competition and revenue.
- Other principal risks include continued operating losses and dependence on one product; competing cancer therapies; adverse effects and regulatory limitations; uncertain reimbursement and pricing pressure; clinical-trial and regulatory uncertainty; covenant and financing constraints; and reliance on Pfizer-licensed rights.
- Management and KPMG reported effective internal control over financial reporting, and KPMG issued an unqualified opinion on the audited financial statements and controls. KPMG identified estimating product-revenue variable consideration, especially provider chargebacks and government rebates, as a critical audit matter.
Most important facts for investors to verify
- Whether product sales, bottle volumes and net revenue reserves stabilize, and how sublicense and royalty revenue compare with recurring product revenue.
- Unrestricted cash runway after the Hsu settlement payment, contractual trial and manufacturing commitments, and required cash and revenue covenants under the Athyrium notes.
- Final status and cash impact of the Hsu settlement and the damages outcome in the remanded Eshelman case.
- Progress, enrollment and results for ongoing neratinib trials, including whether any additional indications receive regulatory approval.
- NERLYNX access, pricing and competitive position, as well as sublicensee execution and generic-entry or patent-litigation developments in the U.S. and China.